


Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections

Jake Dickinson, Claire Patterson, Parmesh Gajjar and Paul A Dickinson

Seda Pharmaceutical Development Services Ltd, Alderley Park, Alderley Edge, SK10 4TG


Email: jake.dickinson@sedapds.com Telephone: +44(0)7518528830



PURPOSE

- Linear in vitro in vivo correlation (IVIVC) methods of both oral and non-oral dosage forms are reported [1-5], however linear IVIVC may be inappropriate for complex parenterals.
- For long-acting injections (LAIs), with complex release profiles, it is likely that a non-linear relationship is required to correlate accelerated in vitro release to real time in vivo release.
- Figure 1 is a flow chart of the proposed methodology to perform non-linear IVIVC of a LAI

Figure 1 Flow chart of IVIVC methodology



OBJECTIVE

Establish methodology for non-linear level A IVIVC.

METHODS

- To demonstrate the steps required for non-linear IVIVC, we simulated datasets for accelerated in vitro dissolution and PK profiles for three different formulations that are typical of a parenteral PLGA microsphere product.

Steps to perform non-linear IVIVC

- Deconvolution of the absorption profile of each formulation
- Model dissolution profiles and calculate scaled in vitro timepoints
- Creating a Levy plot, by plotting in vivo timepoints against the scaled in vitro timepoints. The IVIVC is said to be non-linear if the Levy plot is best described by a non-linear function
- Generation of a scaled dissolution profile
- Simulation of PK profiles using scaled dissolution. Assessment of the resulting IVIVC against the guideline criteria set by the FDA [1]

RESULTS

Establishing an IVIVC

- IVIVC was established on 3 different formulations. To highlight the steps taken for IVIVC we present one formulation in detail:
- Simulated PK data was modelled using compartmental PK analysis (Figure 2a) resulting in the deconvolution of the absorption profiles (Figure 2b).
- A second order polynomial gave a satisfactory fit of the dissolution data (Figure 2c). Thus, scaled in vitro timepoints were calculated.
- Figure 2d shows in vivo absorption is slower than in vitro dissolution
- A levy plot was generated of the scaled in vitro timepoints and the measured in vivo timepoints and regressed against using linear and non-linear models, as shown in Figure 3a and 3b
- The established model was used to calculate scaled dissolution profiles
- Figure 3c and 3d illustrates, scaled dissolution profiles compared to the dissolution profile and absorption profile
- Figure 3e and 3f shows the predicted PK profile convoluted from the scaled dissolution profile
- Non-linear IVIVC predicted the PK well, however linear IVIVC gave an unsatisfactory prediction

Validation

- Criteria for a valid IVIVC is specified by the FDA[1]
- To validate the established non-linear IVIVC the mean scaled in vitro time at each associated absorption time point was calculated and used to convolute the PK profiles of each formulation
- A valid IVIVC was established:
 - Mean absolute percent prediction error (MAPPE) was less than 10% for C_{max} and AUC
 - Percent prediction error (%PE) of C_{max} and AUC for each formulation was less than 15%
- The %PE's are summarised in Table 1

Figure 2 Deconvolution of absorption profile and modelling of dissolution data




Figure 3 Comparison of linear (top) and non-linear (bottom) IVIVC approaches. From left to right: fitted Levy plots, mean scaled in vitro profile, predicted PK from established IVIVC




Table 1 Observed (Obs) and predicted (Pred) C_{max} and AUC following non-linear IVIVC and the associated percent error for each formulation.

Formulation	Obs C_{max} (ng/mL)	Pred C_{max} (ng/mL)	C_{max} % PE	Obs AUC (ng*h/mL)	Pred AUC (ng*h/mL)	AUC % PE
1	59.65	56.83	4.73	26457	26404	0.2
2	54.18	51.97	4.08	24091	24188	0.4
3	64.51	59.51	7.75	29203	27673	5.24
MAPPE			5.52			1.95

CONCLUSIONS

- As the release from LAIs can be prolonged over weeks or months, accelerated in vitro dissolution testing is very desirable.
- However, due to the complexity of LAI formulation, this acceleration can affect the different phases of drug release in different ways meaning that a linear IVIVC model may/will not be appropriate.
- In this work, we have demonstrated a step-by-step approach for non-linear IVIVC using higher order polynomials.
- The results showed that in this instance, where dissolution was much faster than absorption and the complexity of the release profile was high, a linear IVIVC was invalid and said to be inconclusive whereas a non-linear approach led to a valid IVIVC.
- We believe that this an important first step in establishing IVIVC for complex dosage forms.
- We hope this encourages development scientists to attempt to establish an IVIVC regardless of the complexity of a dosage form. Thus, more time can be spent on formulation work and less time and money spent testing in animals and humans.

REFERENCES

- FDA Guidance for Industry Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations (1997)
- Mauger DT & Chinchilli VM (1997) J Biopharm Stat. 1997;7:565-78. <https://doi.org/10.1080/10543409708835207>
- Bhalan G, Timmins P, Greene DS, Marathe PH J Pharm Sci. 2001; 90:1176-85. <https://doi.org/10.1002/jps.1071>
- Mohamed MEF., Trueman S, Othman AA et al (2019) AAPS J 21: 108. <https://doi.org/10.1208/s12248-019-0378-y>
- Shen J, Burgess DJ (2015) J. Control. Release 219 644-651. <https://doi.org/10.1016/j.jconrel.2015.09.052>
- Dickinson J, Patterson CM, Gajjar P, Dickinson H and Dickinson PA Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections *In preparation*

